RxDoctor Payments Data

Michael Chisner, MD

Clinical Cardiac Electrophysiology · Savannah, GANPI 1720051261

Payments from drug & device makers

$11,637in general payments, 2019–2025

Across 236 payments — averaging $49.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Abbott$2K
  • Medical Device Business Services, Inc.$2K
  • Biosense Webster, Inc.$1K
  • Novartis$418
  • Atricure, Inc.$206
  • plus $859 from 14 others
$2,483in research payments, 2019–2025

Across 5 payments — averaging $496.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Boston Scientific$2K

What the payments were for

  • Speaking & faculty fees$2,50021%
  • Travel & lodging$2,51122%
  • Food & beverage$6,62757%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,637 in reported general payments places this provider in the 25th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

See all clinical cardiac electrophysiology providers in Georgia

Medicare billing

Part B allowed, 2024
$324,601
Medicare patients
764
Services billed
4,513

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban413$379,105
XareltoRivaroxaban261$212,363
EntrestoSacubitril/Valsartan56$46,741
Flecainide Acetate158$7,567
SotalolSotalol Hcl95$1,656
Metoprolol Succinate151$1,555
Potassium Chloride70$1,377
Midodrine Hcl15$1,173
Digoxin33$1,153
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$1,057
Sotalol AfSotalol Hcl14$1,021
Bisoprolol Fumarate22$981
Carvedilol93$872
Warfarin Sodium75$692
Amiodarone Hcl47$562

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$136$379,105413 claims
Johnson & JohnsonXarelto$23$212,363261 claims
NovartisEntresto$418$46,74156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 93 clinical cardiac electrophysiology providers in Georgia.

Other clinical cardiac electrophysiology in Savannah

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →